^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GSK3745417

    i
    Other names: GSK3745417, GSK 3745417, GSK-3745417
    Associations

    News

    Trials
    Company:
    GSK
    Drug class:
    STING agonist
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS (clinicaltrials.gov)
    P1, N=18, Terminated, GlaxoSmithKline | Active, not recruiting --> Terminated; The protocol was terminated on the basis of a reprioritization of organizational allocation of resources for clinical research programs.
    Trial termination
    |
    GSK3745417
    5ms
    A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=97, Active, not recruiting, GlaxoSmithKline | Trial primary completion date: Mar 2025 --> Apr 2024
    Trial primary completion date • Metastases
    |
    Jemperli (dostarlimab-gxly) • GSK3745417
    7ms
    A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=98, Active, not recruiting, GlaxoSmithKline | Trial completion date: Apr 2024 --> Mar 2025 | Trial primary completion date: Apr 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • GSK3745417
    11ms
    A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=72 --> 18 | Trial completion date: Dec 2025 --> Mar 2024 | Trial primary completion date: Dec 2025 --> Mar 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    GSK3745417
    1year
    Phase 1 First Time in Human (FTIH), Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=98, Active, not recruiting, GlaxoSmithKline | Trial completion date: Aug 2024 --> Apr 2024
    Trial completion date • Metastases
    |
    Jemperli (dostarlimab-gxly) • GSK3745417
    over1year
    Phase 1 First Time in Human (FTIH), Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=97, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=300 --> 97 | Trial completion date: May 2025 --> Aug 2024 | Trial primary completion date: Nov 2024 --> Apr 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    Jemperli (dostarlimab-gxly) • GSK3745417
    over1year
    STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME: A FIRST-IN- CLINIC PHASE 1 STUDY OF GSK3745417 (EHA 2023)
    Accrual is ongoing. Clinical trial information: NCT05424380. Acute myeloid leukemia, Clinical trial, MDS, MDS/AML
    P1 data
    |
    STING (stimulator of interferon response cGAMP interactor 1) • IFNA1 (Interferon Alpha 1) • IFNB1 (Interferon Beta 1)
    |
    GSK3745417
    2years
    Sting Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples (ASH 2022)
    GSK3745417 also blocked colony formation in primary AML samples from 5 donors.GSK3745417 is able to induce growth inhibition with transient compound incubation in vitro in as little as 30 minutes to 1 hour. Taken together, this data suggests a role for GSK3745417 as a therapeutic in AML/MDS indications through dual mechanisms of direct tumor cell killing and immune activation at a clinically relevant dose.The human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol.
    Preclinical
    |
    STING (stimulator of interferon response cGAMP interactor 1) • IFNB1 (Interferon Beta 1)
    |
    GSK3745417